Sandoz announces agreement to acquire Aspen?s Japanese operations and associated assets, strengthening position in world?s third largest generics market
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
Sandoz announces agreement to acquire Aspen?s Japanese operations and associated assets, strengthening position in world?s third largest generics market
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
Email:?investor.relations@novartis.com
- Planned acquisition reinforces Sandoz strategic focus on Japan
- Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands
- Medicines complement Sandoz broad hospital portfolio and pipeline in Japan thereby expanding access to the hospital channel
Antonio Ligi | |
Novartis Global Media Relations | |
+41613241374 (direct) | |
antonio.ligi@novartis.com | |
Steffen Kurzawa | Michelle Bauman |
Sandoz Global Communications | Sandoz Global Communications |
+49 170 901 2622 (mobile) | +1 973 714 8043 (mobile) |
steffen.kurzawa@sandoz.com | michelle.bauman@sandoz.com? |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 862 778 3258 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |